Abbott Laboratories (ABT) Competitors $127.32 +1.13 (+0.90%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$127.35 +0.03 (+0.02%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABT vs. DXCM, ISRG, TSLA, ABBV, BSX, ELV, ITGR, JNJ, MDT, and TMOShould you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include DexCom (DXCM), Intuitive Surgical (ISRG), Tesla (TSLA), AbbVie (ABBV), Boston Scientific (BSX), Elevance Health (ELV), Integer (ITGR), Johnson & Johnson (JNJ), Medtronic (MDT), and Thermo Fisher Scientific (TMO). Abbott Laboratories vs. Its Competitors DexCom Intuitive Surgical Tesla AbbVie Boston Scientific Elevance Health Integer Johnson & Johnson Medtronic Thermo Fisher Scientific Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Do analysts recommend ABT or DXCM? Abbott Laboratories currently has a consensus target price of $144.47, indicating a potential upside of 13.47%. DexCom has a consensus target price of $99.89, indicating a potential upside of 26.00%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Abbott Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abbott Laboratories 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.91DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95 Which has more volatility and risk, ABT or DXCM? Abbott Laboratories has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Is ABT or DXCM more profitable? Abbott Laboratories has a net margin of 32.43% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Abbott Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Abbott Laboratories32.43% 18.32% 10.71% DexCom 13.29%30.41%10.08% Which has higher valuation and earnings, ABT or DXCM? Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbott Laboratories$43.11B5.14$13.40B$7.9815.95DexCom$4.30B7.23$576.20M$1.4455.06 Does the media prefer ABT or DXCM? In the previous week, Abbott Laboratories had 11 more articles in the media than DexCom. MarketBeat recorded 63 mentions for Abbott Laboratories and 52 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.54 beat DexCom's score of 0.98 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 59 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Very Positive DexCom 25 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ABT or DXCM? 75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryAbbott Laboratories beats DexCom on 9 of the 17 factors compared between the two stocks. Get Abbott Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABT vs. The Competition Export to ExcelMetricAbbott LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$219.55B$10.40B$5.48B$20.68BDividend Yield1.84%1.99%4.73%3.67%P/E Ratio15.9518.4228.6729.07Price / Sales5.1429.01373.9066.27Price / Cash19.1722.3135.4522.84Price / Book4.363.478.274.43Net Income$13.40B$234.77M$3.24B$994.22M7 Day Performance0.62%-4.82%-3.69%-3.35%1 Month Performance-5.04%1.80%4.33%-2.06%1 Year Performance14.40%-12.51%25.95%10.15% Abbott Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABTAbbott Laboratories4.983 of 5 stars$127.32+0.9%$144.47+13.5%+15.6%$219.55B$43.11B15.95114,000Positive NewsDXCMDexCom4.9727 of 5 stars$87.58+1.0%$99.60+13.7%+12.7%$34.35B$4.03B65.3810,300Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionISRGIntuitive Surgical4.7381 of 5 stars$496.40+1.6%$592.05+19.3%+7.1%$177.76B$8.35B69.1715,638Positive NewsInsider TradeTSLATesla4.2499 of 5 stars$312.94+2.5%$302.75-3.3%+39.6%$1.01T$97.69B181.03125,665Trending NewsAnalyst ForecastShort Interest ↑ABBVAbbVie4.5773 of 5 stars$189.72-0.6%$211.29+11.4%+2.9%$334.90B$57.37B80.6855,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionBSXBoston Scientific4.5367 of 5 stars$106.36+0.1%$117.50+10.5%+40.2%$157.53B$18.49B63.3853,000Trending NewsInsider TradeELVElevance Health4.9513 of 5 stars$291.89+4.1%$418.19+43.3%-48.5%$65.95B$189.25B12.46104,200Positive NewsITGRInteger3.3358 of 5 stars$106.75-0.3%$142.75+33.7%-8.2%$3.73B$1.75B50.6711,000JNJJohnson & Johnson4.6709 of 5 stars$168.10-0.9%$174.50+3.8%+4.1%$404.04B$88.82B17.96138,100Trending NewsAnalyst RevisionMDTMedtronic4.5626 of 5 stars$92.40+0.1%$98.19+6.3%+11.0%$118.44B$33.54B25.5195,000Positive NewsTMOThermo Fisher Scientific4.9919 of 5 stars$478.62+0.8%$593.00+23.9%-25.6%$180.58B$42.88B27.67125,000Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies DXCM Alternatives ISRG Alternatives TSLA Alternatives ABBV Alternatives BSX Alternatives ELV Alternatives ITGR Alternatives JNJ Alternatives MDT Alternatives TMO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABT Stock Alerts